Terminated

4

9

Canada

tinzaparin, Rivaroxaban

Sunnybrook Health Sciences Centre, LEO Pharma, Sunnybrook Research Institute

Deep Vein Thrombosis, Post Thrombotic Syndrome

01/24

01/24

Active, not recruiting

3

88

Canada

Micronized Purified Flavonoid Fraction, Venixxa group, Placebo, Placebo group

Sir Mortimer B. Davis - Jewish General Hospital

Post-Thrombotic Syndrome

03/24

05/24

Active, not recruiting

2

456

Europe, Canada, Japan, US, RoW

LY3540378, Placebo

Eli Lilly and Company

Heart Failure, Heart Failure With Preserved Ejection Fraction

01/25

01/25

Recruiting

4

1500

Europe, Canada, RoW

Ciprofloxacin, Cipro, Placebo

Clinical Urology and Epidemiology Working Group, University of Helsinki, Helsinki University Central Hospital, University of Western Ontario, Canada, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, King Abdulaziz University, Hospital Sao Luiz, St. Petersburg State Pavlov Medical University, University Hospital, Basel, Switzerland, Tallaght University Hospital, Tabriz University of Medical Sciences, Dr Cipto Mangunkusumo General Hospital

Ureteral Stones, Ureteral Calculi, Nephrolithiasis

12/24

12/24

Active, not recruiting

3

800

Canada

PSMA PET/CT guided intensification of therapy, Control Arm

Centre hospitalier de l'Université de Montréal (CHUM), Canadian Cancer Society (CCS), Lantheus Medical Imaging, British Columbia Cancer Agency, London Health Sciences Centre, Princess Margaret Hospital, Canada, Tom Baker Cancer Centre, McMaster University, Institute of Health Economics, Canada, Queen's University

Prostate Cancer

01/29

01/29

Completed

N/A

24

Canada

Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Canadian Urological Association, Kidney Cancer Canada

Renal Cyst

08/21

12/22

Recruiting

4

8000

Europe, Canada, RoW

Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging

University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute

Staphylococcus Aureus Bacteremia

12/28

12/28

Completed

3

4800

Europe, Canada, US, RoW

Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix

McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia

Gastrointestinal Hemorrhage (Clinically Important, Upper)

10/23

01/24

Recruiting

3

20000

Europe, Canada, Japan, US, RoW

Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir

UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore

Community-acquired Pneumonia, Influenza, COVID-19

02/26

02/28

Not yet recruiting

N/A

6500

NA

1- Vasopressors - Mean arterial pressure 55-59, 2- Vasopressors - Mean arterial pressure 60-65, 3- Vasopressors - Mean arterial pressure 66-69, 4- Vasopressors - Mean arterial pressure 70-75

Université de Sherbrooke

Intensive Care Unit ICU

12/29

06/30

Active, not recruiting

N/A

52

Canada

Methotrexate, Trexall, Ondansetron, Zofran, Folic/folinic acid, Leucovorin

University of British Columbia, The Arthritis Society, Canada, University of Calgary, The Hospital for Sick Children, McGill University Health Centre/Research Institute of the McGill University Health Centre, London Health Sciences Centre, University of Manitoba, Alberta Children's Hospital, McMaster University, McMaster Children's Hospital, Université de Montréal

Juvenile Idiopathic Arthritis

10/24

03/25

Withdrawn

3

80

Canada

Bromocriptine, Guideline-driven medical therapy (GDMT)

Montreal Heart Institute, Canadian Cardiovascular Society

Peripartum Cardiomyopathy

01/23

01/23

Recruiting

N/A

150

Canada

CardioMems

Montreal Heart Institute

Chronic Heart Failure

12/25

12/25

Terminated

N/A

9

Canada

MitraClip, Medical Therapy

Montreal Heart Institute, Abbott Medical Devices

Ventricular Remodeling, Left

03/24

05/24

Recruiting

N/A

1360

Canada

NT-proBNP, AI echocardiogram, electrocardiogram, Cardiovascular physical examination

Cardiology Research UBC, AstraZeneca, Centre for Cardiovascular Innovation, NHS Greater Glasgow & Clyde, HeartLife Foundation, Canadian Heart Function Alliance, Montreal Heart Institute

Heart Failure

01/27

01/29

Active, not recruiting

3

408

Canada

Metformin, Metformin hydrochloride, Placebo, Placebo tablet

University Health Network, Toronto

Prostate Cancer

02/24

08/24

Recruiting

N/A

6000

Canada, US, RoW

Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor

McMaster University, Prostate Cancer Canada, Canadian Cancer Society (CCS)

Prostate Cancer, Cardiovascular Disease

Recruiting

2

20

Canada

Radiopharmaceutical 68Ga-DOTATATE

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Neuroblastoma

12/26

09/27

Recruiting

N/A

60

Canada

Adjustable Transobturator Male System, Artificial Urinary Sphincter

Université de Sherbrooke

Post-Prostatectomy Incontinence, Urinary Stress Incontinence, Urinary Incontinence, Stress Incontinence, Male

01/24

01/25